Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fluorouracil + Mitomycin C |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
Mitomycin C | Mitozytrex | Chemotherapy - Alkylating 18 | Mitomycin C is an antibiotic alkylating agent, which cross-links DNA to prevent DNA synthesis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04230759 | Phase II | Durvalumab + Fluorouracil + Mitomycin C Fluorouracil + Mitomycin C | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group (RADIANCE) | Active, not recruiting | DEU | CHE | AUT | 0 |
NCT03775265 | Phase III | Atezolizumab + Cisplatin + Mitomycin C Fluorouracil + Mitomycin C Atezolizumab + Gemcitabine + Mitomycin C Gemcitabine + Mitomycin C Atezolizumab + Fluorouracil + Mitomycin C Cisplatin + Mitomycin C | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
NCT04929028 | Phase II | Capecitabine + Mitomycin C Nivolumab Fluorouracil + Mitomycin C | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Recruiting | USA | 0 |